179 related articles for article (PubMed ID: 11914909)
21. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
22. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
Campos SM; Penson RT; Mays AR; Berkowitz RS; Fuller AF; Goodman A; Matulonis UA; Muzikansky A; Seiden MV
Gynecol Oncol; 2001 May; 81(2):206-12. PubMed ID: 11330951
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Rose PG; Blessing JA; Lele S; Abulafia O
Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
[TBL] [Abstract][Full Text] [Related]
26. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
[TBL] [Abstract][Full Text] [Related]
27. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Esteva FJ; Rivera E; Cristofanilli M; Valero V; Royce M; Duggal A; Colucci P; DeJager R; Hortobagyi GN
Cancer; 2003 Sep; 98(5):900-7. PubMed ID: 12942555
[TBL] [Abstract][Full Text] [Related]
28. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
Eichbaum MH; Schuetz F; Khbeis T; Lauschner I; Foerster F; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Sep; 18(8):963-8. PubMed ID: 17667603
[TBL] [Abstract][Full Text] [Related]
29. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.
Kouloulias VE; Dardoufas CE; Kouvaris JR; Gennatas CS; Polyzos AK; Gogas HJ; Sandilos PH; Uzunoglu NK; Malas EG; Vlahos LJ
Clin Cancer Res; 2002 Feb; 8(2):374-82. PubMed ID: 11839652
[TBL] [Abstract][Full Text] [Related]
30. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
Rose PG; Maxson JH; Fusco N; Mossbruger K; Rodriguez M
Gynecol Oncol; 2001 Aug; 82(2):323-8. PubMed ID: 11531287
[TBL] [Abstract][Full Text] [Related]
31. A unified definition of clinical anthracycline resistance breast cancer.
Pivot X; Asmar L; Buzdar AU; Valero V; Hortobagyi G
Br J Cancer; 2000 Feb; 82(3):529-34. PubMed ID: 10682660
[TBL] [Abstract][Full Text] [Related]
32. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP
Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
[TBL] [Abstract][Full Text] [Related]
33. [Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors].
Rainer H; Gössinger H; Lenzhofer R; Moser K; Schneeweiss B
Wien Med Wochenschr; 1983; 133(7):183-7. PubMed ID: 6868630
[TBL] [Abstract][Full Text] [Related]
34. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
Palmieri C; Misra V; Januszewski A; Yosef H; Ashford R; Keary I; Davidson N
Clin Breast Cancer; 2014 Apr; 14(2):85-93. PubMed ID: 24325950
[TBL] [Abstract][Full Text] [Related]
35. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer.
Leitner SP; Casper ES; Hakes TB; Kaufman RJ; Winn RJ; Scoppetuolo M; Raymond V; Geller NL; Young CW
Cancer Treat Rep; 1985 Nov; 69(11):1319-20. PubMed ID: 4092194
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer.
Ingle JN; Ahmann DL; O'Fallon JR; Bisel HF; Rubin J; Kvols LK; Giuliani ER
Cancer Treat Rep; 1979; 63(11-12):1701-5. PubMed ID: 526908
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
[TBL] [Abstract][Full Text] [Related]
39. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
O'Brien ME
Anticancer Drugs; 2008 Jan; 19(1):1-7. PubMed ID: 18043124
[TBL] [Abstract][Full Text] [Related]
40. An oriented phase II trial of THP-adriamycin in breast carcinoma.
Mathé G; Umezawa H; Oka S; Misset JL; Brienza S; de Vassal F; Musset M; Ribaud P; Tapiero H
Biomed Pharmacother; 1986; 40(10):376-9. PubMed ID: 3580506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
